CHM
0.003
50%
M2R
0.002
-33.3%
LNU
0.003
50%
CXU
0.016
-27.3%
SFG
0.003
50%
CNJ
0.006
-25%
MVF
0.88
44.3%
FBR
0.003
-25%
C29
0.026
36.8%
VHM
0.355
-24.5%
IS3
0.023
35.3%
AUR
0.016
-23.8%
C7A
0.004
33.3%
BCK
0.014
-22.2%
AVA
0.068
25.9%
AYT
0.004
-20%
OEL
0.005
25%
YRL
0.24
-20%
VEN
0.005
25%
RAS
0.031
-18.4%
FLG
0.19
22.6%
MYX
3.65
-18%
ALV
0.057
21.3%
ALM
0.005
-16.7%
GTK
7.97
20.6%
GTE
0.015
-16.7%
RDN
0.006
20%
M4M
0.005
-16.7%
QUB
4.86
19.4%
RWD
0.04
-14.9%
DEV
0.165
17.9%
PHX
0.115
-14.8%
PSL
0.033
17.9%
HAL
0.042
-14.3%
HHR
0.007
16.7%
HIQ
0.018
-14.3%
KRR
0.014
16.7%
OVT
0.006
-14.3%
MGU
0.007
16.7%
RGL
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759